

# Accepted Manuscript

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Claudia Brandt, Petra Hillmann, Andreas Noack, Kerstin Römermann, Leon A. Öhler, Denise Rageot, Florent Beaufils, Anna Melone, Alexander M. Sele, Matthias P. Wymann, Dorian Fabbro, Wolfgang Löscher

PII: S0028-3908(18)30468-4

DOI: [10.1016/j.neuropharm.2018.08.002](https://doi.org/10.1016/j.neuropharm.2018.08.002)

Reference: NP 7287

To appear in: *Neuropharmacology*


Received Date: 21 March 2018

Revised Date: 9 July 2018

Accepted Date: 2 August 2018

Please cite this article as: Brandt, C., Hillmann, P., Noack, A., Römermann, K., Öhler, L.A., Rageot, D., Beaufils, F., Melone, A., Sele, A.M., Wymann, M.P., Fabbro, D., Löscher, W., The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy, *Neuropharmacology* (2018), doi: 10.1016/j.neuropharm.2018.08.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy**

Claudia Brandt<sup>1,2\*</sup>, Petra Hillmann<sup>3\*</sup>, Andreas Noack<sup>1,2</sup>, Kerstin Römermann<sup>1,2</sup>, Leon A. Öhler<sup>1</sup>, Denise Rageot<sup>4</sup>, Florent Beaufils<sup>3</sup>, Anna Melone<sup>4</sup>, Alexander M. Sele<sup>4</sup>, Matthias P. Wymann<sup>4</sup>, Dorian Fabbro<sup>3</sup>, and Wolfgang Löscher<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany

<sup>2</sup>Center for Systems Neuroscience, Hannover, Germany

<sup>3</sup>PIQUR Therapeutics AG, Basel, Switzerland

<sup>4</sup>Department of Biomedicine, University of Basel, Basel, Switzerland

\* Contributed equally

**Correspondence:**

Dr. W. Löscher, Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Bünteweg 17, D-30559 Hannover, Germany; Phone: +49-511-856-8720; Fax: +49-511-953-8581; E-mail: [wolfgang.loescher@tiho-hannover.de](mailto:wolfgang.loescher@tiho-hannover.de)

**Abbreviations**

AKT, protein kinase B; ASD, anti-seizure drug; 4E-BP1, initiation factor 4E binding protein; HP $\beta$ CD, hydroxypropyl- $\beta$ -cyclodextrin; *MTD*, maximal tolerated dose; MES-T, maximal electroshock seizure threshold; mTORC, mammalian target of rapamycin complex; PBS, phosphate buffered saline; PI3K, phosphoinositide 3-kinase; PK, pharmacokinetics; rictor, rapamycin-insensitive companion of mammalian target of rapamycin; S6K, ribosomal S6 kinase; S6-rp, S6 ribosomal protein; SE, status epilepticus; TID, threshold increasing dose; TLE, temporal lobe epilepsy; TSC, tuberous sclerosis complex; ULK, UNC-5 like autophagy activating kinase complex.

Download English Version:

<https://daneshyari.com/en/article/8516213>

Download Persian Version:

<https://daneshyari.com/article/8516213>

[Daneshyari.com](https://daneshyari.com)